Author

OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« Federal Circuit Affirms Invalidity of AstraZeneca's Toprol-XL Patent | Main | Ranbaxy and GSK Reach Settlement on Launch of Generic Valtrex »

July 27, 2007

Pharma News Briefs

  • FDA Law Blog reported Monday that the proposed follow-on biologics legislation is in serious jeopardy in Congress.  Pharmalot had a similar report last Friday.
  • Meanwhile, European regulators recently granted approval to three new biosimilar drugs, as Patent Docs reports today.
  • The San Francisco Chronicle recently published a nice article summarizing the debate over generic biotech drugs.
  • The Business Standard recently reported on incentives for Indian drug companies to develop generic biotech drugs.
  • Peter Zura's 271 blog had this interesting post Wednesday on controversy caused by reaction of the Indian generic pharmaceutical industry to patent reform legislation in Congress.
  • MarketWatch had this article last weekend examining the leveling off of pharmaceutical prices in America.
  • Par and J&J announced they have settled their generic Ultracet patent litigation: MarketWatch; Patent Docs.
  • IMPAX announced a district court ruling relating to generic Rilutek: PharmaLive; UPI.

Posted by Aaron Barkoff in Paragraph IV Litigation, Pharma Business News |

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.